SG11202004581PA - Partial agonists of interleukin-2 - Google Patents
Partial agonists of interleukin-2Info
- Publication number
- SG11202004581PA SG11202004581PA SG11202004581PA SG11202004581PA SG11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA
- Authority
- SG
- Singapore
- Prior art keywords
- interleukin
- partial agonists
- agonists
- partial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589497P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062122 WO2019104092A1 (en) | 2017-11-21 | 2018-11-20 | Partial agonists of interleukin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004581PA true SG11202004581PA (en) | 2020-06-29 |
Family
ID=66631137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004581PA SG11202004581PA (en) | 2017-11-21 | 2018-11-20 | Partial agonists of interleukin-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200299349A1 (en) |
| EP (1) | EP3713592A4 (en) |
| JP (2) | JP7464278B2 (en) |
| KR (1) | KR20200086722A (en) |
| CN (1) | CN111615396A (en) |
| AU (2) | AU2018372167B2 (en) |
| BR (1) | BR112020009920A2 (en) |
| CA (1) | CA3082904A1 (en) |
| IL (1) | IL274723A (en) |
| MX (1) | MX2020005041A (en) |
| RU (1) | RU2020120145A (en) |
| SG (1) | SG11202004581PA (en) |
| WO (1) | WO2019104092A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP2020521452A (en) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | Targeted tolerance |
| MA49770A (en) | 2017-08-03 | 2021-05-26 | Synthorx Inc | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP2022533702A (en) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM-targeted immune tolerance |
| CN110642934B (en) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | Long-acting interleukin-2 of target regulatory T cell and application thereof in treating autoimmune disease |
| AU2020407233A1 (en) | 2019-12-20 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Novel IL2 agonists and methods of use thereof |
| AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| CA3166509A1 (en) * | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| IL294388A (en) | 2020-01-14 | 2022-08-01 | Synthekine Inc | Il2 orthologs and methods of use |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021253360A1 (en) * | 2020-06-18 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| US20240009317A1 (en) * | 2021-03-31 | 2024-01-11 | Hanmi Pharm. Co., Ltd. | Novel conjugate of immune-stimulating il-2 analog and preparation method thereof |
| CA3222358A1 (en) | 2021-07-09 | 2023-01-12 | Vijaya Raghavan PATTABIRAMAN | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| EP4366782A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
| EP4366778A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Antibody conjugates and manufacture thereof |
| WO2023161857A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
| WO2023200796A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Immune cell inhibition by immune checkpoint engagers |
| WO2024044716A2 (en) * | 2022-08-26 | 2024-02-29 | Sonoma Biotherapeutics, Inc. | Tethered interleukin-2 recombinant receptors and methods of use |
| WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2788A1 (en) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Selective IL-2 agonists and antagonists. |
| RS20050501A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| MX2007009012A (en) * | 2005-01-27 | 2007-09-14 | Novartis Vaccines & Diagnostic | Methods for treating renal cell carcinoma. |
| US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| HUE054318T2 (en) * | 2010-11-12 | 2021-08-30 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| EP2655409A4 (en) * | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Superagonists and antagonists of interleukin-2 |
| CA2931114A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
-
2018
- 2018-11-20 KR KR1020207017428A patent/KR20200086722A/en not_active Application Discontinuation
- 2018-11-20 BR BR112020009920-1A patent/BR112020009920A2/en unknown
- 2018-11-20 JP JP2020545077A patent/JP7464278B2/en active Active
- 2018-11-20 CN CN201880086929.7A patent/CN111615396A/en active Pending
- 2018-11-20 RU RU2020120145A patent/RU2020120145A/en unknown
- 2018-11-20 SG SG11202004581PA patent/SG11202004581PA/en unknown
- 2018-11-20 MX MX2020005041A patent/MX2020005041A/en unknown
- 2018-11-20 US US16/765,617 patent/US20200299349A1/en not_active Abandoned
- 2018-11-20 EP EP18881013.9A patent/EP3713592A4/en active Pending
- 2018-11-20 CA CA3082904A patent/CA3082904A1/en active Pending
- 2018-11-20 WO PCT/US2018/062122 patent/WO2019104092A1/en unknown
- 2018-11-20 AU AU2018372167A patent/AU2018372167B2/en active Active
-
2020
- 2020-05-17 IL IL274723A patent/IL274723A/en unknown
-
2021
- 2021-05-13 US US17/320,174 patent/US20210269498A1/en active Pending
-
2024
- 2024-01-19 AU AU2024200355A patent/AU2024200355A1/en active Pending
- 2024-03-21 JP JP2024044912A patent/JP2024079749A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018372167A1 (en) | 2020-06-11 |
| JP2024079749A (en) | 2024-06-11 |
| IL274723A (en) | 2020-07-30 |
| US20200299349A1 (en) | 2020-09-24 |
| BR112020009920A2 (en) | 2020-12-15 |
| CA3082904A1 (en) | 2019-05-31 |
| AU2018372167B2 (en) | 2023-12-07 |
| KR20200086722A (en) | 2020-07-17 |
| AU2024200355A1 (en) | 2024-03-21 |
| EP3713592A4 (en) | 2022-01-12 |
| WO2019104092A1 (en) | 2019-05-31 |
| MX2020005041A (en) | 2020-10-12 |
| RU2020120145A (en) | 2021-12-22 |
| JP7464278B2 (en) | 2024-04-09 |
| EP3713592A1 (en) | 2020-09-30 |
| JP2021508252A (en) | 2021-03-04 |
| CN111615396A (en) | 2020-09-01 |
| US20210269498A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274723A (en) | Partial agonists of interleukin-2 | |
| HK1258509A1 (en) | Gitr agonists | |
| IL272888B1 (en) | Novel uses of piperidinyl-indole derivatives | |
| EP3134102A4 (en) | Superagonists, partial agonists and antagonists of interleukin-2 | |
| IL269196A (en) | Novel inhibitors | |
| HK1255163A1 (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| GB201706477D0 (en) | Modification of polypeptides | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| IL268731A (en) | New uses of anti-sirpg antibodies | |
| ZA202003267B (en) | Novel combinations of defoliants | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL274627A (en) | Solid state form of valbenazine | |
| GB201719639D0 (en) | Setection of biomarkers | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| SI3217978T1 (en) | Compositions comprising substituted benzofuroquinolizine and alpha2-adrenergic agonists | |
| AU201810507S (en) | Part of refrigerator | |
| AU201810512S (en) | Part of refrigerator | |
| IL269659B1 (en) | Purification of an agent of interest | |
| PL3449931T3 (en) | Use of cerebrolysin | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB2557353B (en) | Configuration of wireless-equipped devices | |
| SG11202105136WA (en) | Application of chidamide | |
| GB201720445D0 (en) | Use of TRPV1 agonists | |
| GB201809911D0 (en) | Use of trpv1 agonists | |
| GB201620933D0 (en) | Use of TRPV1 agonists |